- Home
- KIDS vs PRTA Comparison
KIDS vs PRTA Comparison
Compare KIDS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- PRTA
- Stock Information
- Founded
- KIDS 2007
- PRTA 2012
- Country
- KIDS United States
- PRTA Ireland
- Employees
- KIDS N/A
- PRTA N/A
- Industry
- KIDS Medical/Dental Instruments
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- PRTA Health Care
- Exchange
- KIDS Nasdaq
- PRTA Nasdaq
- Market Cap
- KIDS 524.3M
- PRTA 472.1M
- IPO Year
- KIDS 2017
- PRTA N/A
- Fundamental
- Price
- KIDS $16.21
- PRTA $10.04
- Analyst Decision
- KIDS Strong Buy
- PRTA Buy
- Analyst Count
- KIDS 7
- PRTA 9
- Target Price
- KIDS $27.14
- PRTA $13.14
- AVG Volume (30 Days)
- KIDS 185.8K
- PRTA 767.7K
- Earning Date
- KIDS 10-28-2025
- PRTA 11-11-2025
- Dividend Yield
- KIDS N/A
- PRTA N/A
- EPS Growth
- KIDS N/A
- PRTA N/A
- EPS
- KIDS N/A
- PRTA N/A
- Revenue
- KIDS $220,733,000.00
- PRTA $10,341,000.00
- Revenue This Year
- KIDS $19.30
- PRTA N/A
- Revenue Next Year
- KIDS $17.12
- PRTA $602.32
- P/E Ratio
- KIDS N/A
- PRTA N/A
- Revenue Growth
- KIDS 26.08
- PRTA N/A
- 52 Week Low
- KIDS $15.28
- PRTA $4.32
- 52 Week High
- KIDS $32.00
- PRTA $18.88
- Technical
- Relative Strength Index (RSI)
- KIDS 28.78
- PRTA 68.52
- Support Level
- KIDS $17.95
- PRTA $9.58
- Resistance Level
- KIDS $18.52
- PRTA $10.65
- Average True Range (ATR)
- KIDS 0.70
- PRTA 0.48
- MACD
- KIDS -0.13
- PRTA 0.04
- Stochastic Oscillator
- KIDS 18.42
- PRTA 75.70
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.